We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Drug Stops Cancer Growth by Activating Integrin-Based Apoptosis

By LabMedica International staff writers
Posted on 13 Jun 2016
Print article
Image: ProAgio (green) binding to integrin v3 (Photo courtesy of Georgia State University).
Image: ProAgio (green) binding to integrin v3 (Photo courtesy of Georgia State University).
An experimental drug blocks tumor growth by binding to a novel site on the surface receptor integrin alphavbeta3, which activates the apoptotic factor caspase 8 and leads to the death of the cancer cells.

Expression of the integrin alphavbeta3 is altered in various diseases and has been proposed as a drug target. Integrins are transmembrane receptors that mediate the attachment between a cell and the tissues that surround it, such as other cells or the extracellular matrix (ECM). Integrin molecules do not adhere to their appropriate ligands until cells are activated by chemotactic agents or other stimuli. Only then do the integrins undergo the conformational change necessary to confer high binding affinity for the endothelial adhesion molecules.

Investigators at Georgia State University (Atlanta, USA) used a rational design approach to develop a therapeutic protein, which they called ProAgio. This protein was shown to bind to integrin alphavbeta3 outside the classical ligand-binding site.

Results published in the May 31, 2016, online edition of the journal Nature Communications revealed that ProAgio induced apoptosis of integrin alphavbeta3-expressing cells by recruiting and activating caspase 8 to the cytoplasmic domain of integrin alphavbeta3. Caspases (cysteine-aspartic proteases) are a family of protease enzymes playing essential roles in programmed cell death (including apoptosis, pyroptosis, and necroptosis) and inflammation. Activation of caspases ensures that the cellular components are degraded in a controlled manner, carrying out cell death with minimal effect to surrounding tissues.

ProAgio was also found to express potent anti-angiogenic activity and strongly inhibited growth of tumor xenografts in mice, but did not affect the established vasculature. Toxicity analyses demonstrated that ProAgio was not toxic to mice.

"This integrin pair, alphavbeta3, is not expressed in high levels in normal tissue," said senior author Dr. Zhi-Ren Liu, professor of biology at Georgia State University. "In most cases, it is associated with a number of different pathological conditions. Therefore, it constitutes a very good target for multiple disease treatment. We took a unique angle. We designed a protein that binds to a different site. Once the protein binds to the site, it directly triggers cell death. When we are able to kill pathological cells, then we are able to kill the disease."

Related Links:
Georgia State University

Flocked Swab
HydraFlock and PurFlock Ultra
New
Gold Supplier
Dengue ELISA Test
Dengue Virus IgM
New
Immunoassay Analyzer
DxI 9000
New
ELISA Kits
ALLERgen Specific IgE ELISA Kits

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.